The science of prevention‘Prevention’ might be the buzzword of the moment in the pharma industry, but what does it actually mean Share XThe science of preventionhttps://pharmaphorum.com/r-d/views-analysis-r-d/the-science-of-prevention/
Propeller Health: respiring for successDavid Van Sickle is on a mission to transform treatment for respiratory diseases with the company he co-founded, Share XPropeller Health: respiring for successhttps://pharmaphorum.com/r-d/views-analysis-r-d/propeller-health-respiring-for-success/
The real conspiracy in the pharma industryPaul Tunnah on how pharma industry workers can negatively affect patients without even realising it. If you work Share XThe real conspiracy in the pharma industryhttps://pharmaphorum.com/views-and-analysis/the-real-conspiracy-pharma-industry/
Abilify MyCite and innovating in digital healthpharmaphorum’s Paul Tunnah spoke with Otsuka Pharmaceutical’s North America Pharmaceutical Business president and CEO Kabir Nath about the Share XAbilify MyCite and innovating in digital healthhttps://pharmaphorum.com/views-analysis-digital/abilify-mycite-and-innovating-in-digital-health/
Building a new type of pharmaceutical company – a vision for pharma 2.0The definition of healthcare has become incredibly diverse since the turn of the century. It feels like it Share XBuilding a new type of pharmaceutical company – a vision for pharma 2.0https://pharmaphorum.com/views-analysis-sales-marketing/building-new-pharmaceutical-company-pharma-2-0/
Let’s talk about drugsPaul Tunnah asks if we need to rethink pharma’s strict marketing regulations and have a discussion on how Share XLet’s talk about drugshttps://pharmaphorum.com/views-and-analysis/lets-talk-drugs/
JP Morgan Healthcare: where science, tech and finance collideWelcome to 2019! Hopefully by now you’re managing to ease yourself back into things, no doubt with good Share XJP Morgan Healthcare: where science, tech and finance collidehttps://pharmaphorum.com/views-analysis-sales-marketing/jp-morgan-healthcare-science-tech-finance-collide/
Why pharma’s focus on patients requires less patienceHave you missed me? I certainly wouldn’t be so egotistical to assume that anyone has, but bizarrely it’s Share XWhy pharma’s focus on patients requires less patiencehttps://pharmaphorum.com/patients/pharmas-focus-patients-requires-less-patience/
Can ‘design thinking’ revolutionise pharma’s culture?As part of pharmaphorum’s ‘eye-on-innovation’ series, Paul Tunnah speaks to UCB’s head of innovation, Gregory Miller, about how Share XCan ‘design thinking’ revolutionise pharma’s culture?https://pharmaphorum.com/views-and-analysis/can-design-thinking-revolutionise-pharmas-culture/
